Abstract
A holistic understanding of tissue and organ structure and function requires the detection of molecular constituents in their original three-dimensional (3D) context. Imaging mass cytometry (IMC) enables simultaneous detection of up to 40 antigens and transcripts using metal-tagged antibodies but has so far been restricted to two-dimensional imaging. Here we report the development of 3D IMC for multiplexed 3D tissue analysis at single-cell resolution and demonstrate the utility of the technology by analysis of human breast cancer samples. The resulting 3D models reveal cellular and microenvironmental heterogeneity and cell-level tissue organization not detectable in two dimensions. 3D IMC will prove powerful in the study of phenomena occurring in 3D space such as tumor cell invasion and is expected to provide invaluable insights into cellular microenvironments and tissue architecture.
| Original language | English |
|---|---|
| Pages (from-to) | 122-133 |
| Number of pages | 12 |
| Journal | Nature Cancer |
| Volume | 3 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2022 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2021, The Author(s).
Funding
We thank S. Engler and A. Jacobs (University of Zurich), A. B. Sobottka-Brillout and S. Dettwiler (Institute of Pathology and Molecular Pathology, University Hospital Zurich) and F. Prutek (Tissue Biobank, University Hospital Zurich) for technical support. We thank R. A. Wepf (University of Queensland), H. Gnaegi (Diatome AG) and U. Ziegler, A. Käch and G. Barmettler (University of Zurich) for their invaluable guidance with the paraffin ultramicrotomy procedure. We also thank J. Windhager and V. Zanotelli for their advice on computational analysis. L.K. is supported by a Cancer Research UK Grand Challenge grant. The work of B.B. was supported by the Swiss National Science Foundation R’Equip grant 316030-139220, an SNSF Assistant Professorship grant PP00P3-144874, the European Research Council (ERC) grant under the European Union’s Seventh Framework Programme (FP/2007-2013)/ERC grant no. 336921 and under the European Union’s Horizon 2020 Program ERC Consolidator grant no. 866074, the Cancer Research UK IMAXT Grand Challenge grant and a National Institutes of Health HubMAP grant.
| Funders | Funder number |
|---|---|
| Cancer Research UK IMAXT | |
| European Union’s Horizon 2020 Program ERC | 866074 |
| National Institutes of Health | |
| National Cancer Institute | P30CA008748 |
| Seventh Framework Programme | FP/2007-2013, 336921 |
| Cancer Research UK | |
| European Commission | |
| Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung | 316030-139220, PP00P3-144874 |